martes, 27 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 27, 2026

FullPAC, Inc. Issues Spring 2026 Chairman’s Letter

View original at globenewswire.com
FullPAC, Inc. Issues Spring 2026 Chairman’s Letter Virginia Beach, VA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- FullPAC, Inc. (“FullPAC” or the “Company”) (Nasdaq Reserved: GOTV), a premier nonpartisan campaign technology provider for more than 5,000 U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FullPAC is well positioned to serve the growing political spending market as campaign investment builds ahead of the 2028 Presidential election

    80% confidence

  • Advocacy Lab contributes meaningful recurring revenue and serves as a natural entry point into the broader FullPAC platform, strengthening client retention and expanding long-term revenue opportunities

    80% confidence

  • FullPAC is positioned to become the premier public-market pure play on America's growing political campaign industry

    80% confidence

  • Cash flows from Advocacy Lab will cover its direct purchase consideration by March 31, 2026, several months ahead of schedule

    80% confidence

  • Political campaign spending has surged ever higher since Citizens United was decided in 2010

    80% confidence

  • The 2026 election cycle's projected $10.8 billion advertising spending makes it the most expensive non-presidential election cycle in history, marking a more than 20% increase over 2022 midterms

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,994
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,994 hechos verificados con la fuente5,500 documentos fuente archivados
Consulta estos datos → isubstrate.com